Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 490 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Shock Lung Clear all
Terminated Phase 2 Interventional

IC14 Antibodies to Treat Individuals With Acute Lung Injury

NCT00233207
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Lung Diseases
Interventions
IC14
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age

NCT02636868
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Lucinactant delivered via investigational delivery device, nCPAP
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
26 Weeks to 32 Weeks
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

NCT04388826
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Veru-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Scottsdale, Arizona • Saint Louis Park, Minnesota • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

NCT04412668
View directory record Official record
Conditions
SARS-CoV-2 (COVID-19) Severe Pneumonia
Interventions
Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 4 Interventional Results available

Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management

NCT01710891
View directory record Official record
Conditions
Acute Respiratory Distress
Interventions
CMAC videolaryngoscope, Direct Laryngoscopy
Procedure
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 22, 2026, 6:07 AM EDT
Not listed No phase listed Observational

Effect of Randomization to Neuromuscular Blockade on Physical Functional Impairment and Recovery in ARDS

NCT03038906
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Neuromyopathies
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

NCT04374149
View directory record Official record
Conditions
Cytokine Release Syndrome, COVID19
Interventions
Therapeutic Plasma Exchange, Ruxolitinib
Procedure · Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
12 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 22, 2026, 6:07 AM EDT
Completed No phase listed Observational

Short Term Outcomes of Children With Acute Respiratory Distress Syndrome

NCT00142376
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
0 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2005 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060
View directory record Official record
Conditions
COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions
APL-9, Vehicle Control
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 22, 2026, 6:07 AM EDT
Completed No phase listed Observational

The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)

NCT03654352
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Sturgill
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 22, 2026, 6:07 AM EDT
Recruiting Not applicable Interventional

Pediatric Positive End Expiratory Pressure (PEEP) Titration Using Electrical Impedence Tomography (EIT)

NCT06684119
View directory record Official record
Conditions
Pediatric Acute Respiratory Distress Syndrome
Interventions
Electrical Impedance Tomography positive end-expiratory pressure titration
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
0 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

NCT04582201
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
agenT-797
Drug
Lead sponsor
MiNK Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Santa Monica, California • Louisville, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 22, 2026, 6:07 AM EDT
Enrolling by invitation Not applicable Interventional

Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System

NCT04369599
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, COVID-19
Interventions
V/Q System
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Not applicable Interventional Results available

Nasal Noninvasive NAVA in the Very Low Birth Weight Infant

NCT01785563
View directory record Official record
Conditions
Inadequate; Pulmonary Ventilation, Newborn, Infant, Very Low Birth Weight
Interventions
Nasal NIV-NAVA
Device
Lead sponsor
Tarah T Colaizy
Other
Eligibility
7 Days to 1 Year
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Pre-exposure Prophylaxis for SARS-Coronavirus-2

NCT04328467
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 22, 2026, 6:07 AM EDT
Terminated No phase listed Observational

Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection

NCT04356443
View directory record Official record
Conditions
Respiratory Failure, Ventilatory Failure, COVID-19, Pneumonia, ARDS, Human
Interventions
AirGo Respiratory Monitor
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 22, 2026, 6:07 AM EDT
Completed No phase listed Observational Results available

Retrospective Review of Mechanically Ventilated Patients Using a Continuous Data Collection System.

NCT02184208
View directory record Official record
Conditions
Mechanical Ventilation, Acute Respiratory Distress Syndrome, Hypoxic Respiratory Failure
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 35 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

NCT01473264
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions
recombinant human CC10 (rhCC10), placebo
Drug
Lead sponsor
Clarassance, Inc.
Industry
Eligibility
24 Weeks to 29 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Wilmington, Delaware • Baltimore, Maryland • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 22, 2026, 6:07 AM EDT
Not listed Phase 1Phase 2 Interventional

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

NCT04798716
View directory record Official record
Conditions
Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
Interventions
MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
Drug
Lead sponsor
AVEM HealthCare
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Panorama City, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 22, 2026, 6:07 AM EDT
Terminated Phase 1 Interventional Results available

Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)

NCT04870125
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Sepsis
Interventions
Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 22, 2026, 6:07 AM EDT
Not yet recruiting Not applicable Interventional

Trial of Total Lung Protective Ventilation in Adult VV-ECMO Patients With Severe ARDS

NCT07790133
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome), VV ECMO
Interventions
Mechanical Power Targeted Ventilation
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Not applicable Interventional

Assessing the Role of Inclined Positioning in Acute Respiratory Distress Syndrome Patients Recovery

NCT04612608
View directory record Official record
Conditions
ARDS, Human
Interventions
upright bed
Procedure
Lead sponsor
Peter Morris
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 22, 2026, 6:07 AM EDT
Completed Not applicable Interventional

Evaluating Artificial Intelligence-Based Clinical Decision Support for Sepsis and ARDS

NCT07025096
View directory record Official record
Conditions
Sepsis, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Artifical Intelligence-Generated Treatment Recommendations
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 6:07 AM EDT